l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review

Simple item page
datacite.alternateIdentifier.citationMEDICAL ONCOLOGY,Vol.40,,2023
datacite.alternateIdentifier.doi10.1007/s12032-023-02014-9
datacite.creatorTosta Perez, Maria
datacite.creatorHerrera Belen, Lisandra
datacite.creatorLetelier, Pablo
datacite.creatorCalle, Yolanda
datacite.creatorPessoa, Adalberto
datacite.creatorFarias, Jorge G.
datacite.date2023
datacite.subject.englishAcute lymphoblastic leukemia
datacite.subject.englishAsparaginase
datacite.subject.englishAntineoplastic agent
datacite.subject.englishImmunogenicity
datacite.subject.englishHypersensitivity
datacite.titlel-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review
dc.date.accessioned2023-06-08T15:48:12Z
dc.date.available2023-06-08T15:48:12Z
dc.description.abstractl-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the l-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
dc.identifier.urihttps://repositoriodigital.uct.cl/handle/10925/5282
dc.language.isoen
dc.publisherHUMANA PRESS INC
dc.sourceMEDICAL ONCOLOGY
oaire.resourceTypeReview
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science